Purdue Pharma Signs an Agreement with Alivio Therapeutics for its ALV-107
Shots:
- Alivio to receive $14.75M upfront- $260M milestones- license exercise payments and royalties on sales of product from Purdue. Purdue to get an option to add more compounds to the agreement based on Alivio’s inflammation-targeting technology- including an option for equity investment in Alivio
- The company received funding of $3.3M from the US DOD Technology/Therapeutic Development for its ALV-107 program- to further evaluate it in trials including GMP manufacturing and its IND filing
- ALV-107 is a non-opioid treatment based on Alivio’s inflammation-targeting technology- targeted for interstitial cystitis/bladder pain syndrome (IC/BPS) and has shown the reduction in pain in clinical trials
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
